Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). Gadoquatrane is a highly stable MRI contrast agent featuring high relaxivity being studied to evaluate the potential of a substantially lower gadolinium (Gd) dose for p.

Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

Bayer reported mixed Q1 2023 results, matching analyst consensus expectations with regard to profitability and earnings, but missing on topline and guidance. Long term, Bayer remains well-positioned for growth: Bayer's Crop Science Innovation Summit highlighted an ambitious innovation pipeline valued at approximately €30 billion. Anchored on adjusted EPS estimates through 2025, in line with analyst consensus, I see close to ~55% upside; and accordingly, I reiterate a "Strong Buy" recommendation.

Bayer: Easy Deep Value Pitch

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that Ultravist® (iopromide)-300, -370, its iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM) – making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of the breast in adults, as an adjunct to mammography and/or ultrasound. CEM is an emerging modality that combines digital mammography wi.

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective of the study is to demonstrate efficacy of finerenone over placebo in reducing urine albumin to creatinine ratio (UACR) over 6 mo.

Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, today announced its new Senior Bayer Representative and President of Bayer U.S. Sebastian Guth, Bayer's President of Pharmaceuticals Americas, assumes this leadership role, which oversees all Bayer U.S. operations, on June 30, 2023. Guth, who has been with Bayer for 17 years, will retain leadership of the Pharmaceuticals business for the U.S., a critical growth market for the company, and Canada. Bayer.

Bayer Announces Senior Bayer Representative and President of Bayer U.S.

Bayer AG agreed on Thursday to pay $6.9 million to settle claims by New York Attorney General Letitia James that it misled consumers by advertising Roundup weedkiller as safe.

Bayer reaches $6.9 mln settlement with New York over Roundup safety claims

Bayer AG has reached a $6.9 million settlement with New York for allegedly making false and misleading claims regarding the safety of Roundup weedkillers, the state's Attorney General Letitia James said on Thursday.

Bayer reaches $6.9 million settlement with New York over Roundup weedkiller

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, today announced changes to its U.S. Country Leadership Team. Dave Tomasi will be the President, Consumer Health North America (CH NA), effective July 1. Dave, who has been serving as the Chief Commercial Officer for CH NA, joined Bayer in 2019, holding leadership roles in the Consumer Health division, most recently guiding strategy and operations across all functions, including portfolio management, re.

Bayer Announces Changes to U.S. Country Leadership Team

Ambev

Anheuser-Busch InBev

Sanofi

Tencent Holdings Limited

Toronto-Dominion Bank

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The June 2023 Heat Map

BERLIN--(BUSINESS WIRE)--Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas' LNP technology will support Bayer's in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for in.

Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics

German drugmaker Bayer said it was facing supply issues with its popular oral-contraceptive pill Yasmin in India, without giving a reason, and that supply would resume in the "next few days".

Germany's Bayer faces shortage of contraceptive pill Yasmin in India

Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.

Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies

BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers. Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers. Cedilla's small molecules conditionally.

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

BASEL, Switzerland--(BUSINESS WIRE)--The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms. The shift in the healthcare industry is clear, people need.

Bayer Launches Unit to Develop New Precision Health Consumer Products

Medical Properties Trust

Bayer grew revenue and net income last year. Medical Properties Trust is cleaning up its portfolio, and has a current dividend yield around 15%.

2 No-Brainer Stocks to Buy Right Now for Less than $30

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6, 2023. These presentations continue to underscore the company's commitment to drive treatment approaches through science and innovation in the oncology space. Data featuring NUBEQA® (darolutamide) and Xofigo® (radium Ra 223 dichloride) will be showcased at ASCO. NUBEQA data includes results from the DEAR trial,.

Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting

Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.

Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag

Capitalizing on the promise of focused oligopoly-level businesses, in 2019, we bought Corteva stock when DowDuPont broke into three companies. Bayer appears to have bottomed out as its incoming CEO considers spinning off its agriscience giant focused on seeds, crop protection, and related services.

Bayer Agriscience, Shades Of Corteva

WHIPPANY, N.J.--(BUSINESS WIRE)--In honor of Women's Health Month, Bayer is putting a national spotlight on the impact of the underdiscussed and underdiagnosed condition of heavy menstrual bleeding (HMB) and that Mirena® (levonorgestrel-releasing intrauterine system) 52 mg is an FDA-approved IUD to treat heavy periods for up to 5 years in women who choose an IUD for birth control.2 With its new multi-channel campaign Seeing Red, Bayer aims to raise awareness of HMB and a potential treatment opt.

Bayer launches Seeing Red campaign around the treatment of Heavy Menstrual Bleeding (HMB)

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capi.

Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian's first U.S. FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. Asundexian is an inve.

Bayer Receives U.S. FDA Fast Track Designation for asundexian Atrial Fibrillation Program

Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.

Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline

Bayer AG (OTCPK:BAYZF) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Oliver Maier - Head of Investor Relations Werner Baumann - Chief Executive Officer Stefan Oelrich - Head, Pharmaceuticals Division Rodrigo Santos - Head, Crop Science Division Conference Call Participants Michael Leuchten - UBS Richard Vosser - JPMorgan James Quigley - Morgan Stanley Christian Faitz - Kepler Cheuvreux Kirsty Ross-Stewart - Citi Joe Bowden - Bank of America Jo Walton - Credit Suisse Andreas Heine - Stifel Laurent Favre - BNP Sebastian Bray - Berenberg Vincent Andrews - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the First Quarter 2023 Results.

Bayer AG (BAYZF) Q1 2023 Earnings Call Transcript

Deutsche Telekom AG

European stock indices have done well in the past few months as the fear of a recession in the region have abated. In Germany, the DAX index jumped to €16,000, the highest point since January 2022.

DAX index analysis after mixed Bayer, Deutsche Telekom earnings

MELBOURNE, Australia , May 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection) [1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence who have no evidence of metastatic disease by conventional imaging and a positive PSMA-PET/CT [2] at baseline.

News for Bayer AG Stock (BAYRY)